A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease
Latest Information Update: 21 Dec 2024
At a glance
- Drugs Vonoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Phathom Pharmaceuticals
Most Recent Events
- 03 May 2024 Status changed from recruiting to completed.
- 03 Apr 2024 Planned End Date changed from 1 Nov 2024 to 1 May 2024.
- 03 Apr 2024 Planned primary completion date changed from 1 Nov 2024 to 1 May 2024.